Cargando…

Gut microbiome differences between metformin‐ and liraglutide‐treated T2DM subjects

INTRODUCTION: Metformin and glucagon‐like peptide‐1 (GLP‐1) agonists are widely used for treating type two diabetes mellitus (T2DM). While recent studies suggest these drugs might modify the gastrointestinal tract (GIT) microbiome, further confirmation is required from human clinical trials. MATERIA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhang, Saha, Somdutta, Van Horn, Stephanie, Thomas, Elizabeth, Traini, Christopher, Sathe, Ganesh, Rajpal, Deepak K., Brown, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360918/ https://www.ncbi.nlm.nih.gov/pubmed/30815546 http://dx.doi.org/10.1002/edm2.9

Ejemplares similares

Selective Spectrum Antibiotic Modulation of the Gut Microbiome in Obesity and Diabetes Rodent Models
por: Rajpal, Deepak K., et al.
Publicado: (2015)

Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
por: Napolitano, Antonella, et al.
Publicado: (2014)

Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?
por: Dzięgielewska-Gęsiak, Sylwia, et al.
Publicado: (2022)

Effects of vancomycin‐induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects
por: Kim, Eunwoo, et al.
Publicado: (2021)

Response to Article “Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?” [Letter]
por: Panjaitan, Novaria Sari Dewi, et al.
Publicado: (2022)

Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease
por: Ying, Xing, et al.
Publicado: (2023)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice
por: Deng, Hongjun, et al.
Publicado: (2020)

Response to Comment to the Article “Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?” [Response To Letter]
por: Dzięgielewska-Gęsiak, Sylwia, et al.
Publicado: (2022)

Metformin modulates the gut microbiome in broiler breeder hens
por: Van Syoc, Emily, et al.
Publicado: (2022)

The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus
por: Lee, Chae Bin, et al.
Publicado: (2021)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells
por: Lu, Ran, et al.
Publicado: (2018)

Growth hormone treatment does not augment the anti‐diabetic effects of liraglutide in UCD‐T2DM rats
por: Swarbrick, Michael M., et al.
Publicado: (2022)

Association of metformin administration with gut microbiome dysbiosis in healthy volunteers
por: Elbere, Ilze, et al.
Publicado: (2018)

Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome
por: Xing, Chuan, et al.
Publicado: (2022)

Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance
por: Simanenkova, Anna, et al.
Publicado: (2021)

Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats
por: Li, Jinjin, et al.
Publicado: (2017)

Metformin-induced reductions in tumor growth involves modulation of the gut microbiome()
por: Broadfield, Lindsay A., et al.
Publicado: (2022)

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Association Between Metformin and Prevention of Dementia in T2DM Adult Patients
por: dos Santos, Natalia Moles, et al.
Publicado: (2021)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide
por: Matić, Anita, et al.
Publicado: (2021)

Metformin Improves Cognition by Reducing Leaky Gut and Benefiting Gut Microbiome–Goblet Cell–Mucin Axis
por: Yadav, Hariom, et al.
Publicado: (2020)

Airway host-microbiome interactions in chronic obstructive pulmonary disease
por: Wang, Zhang, et al.
Publicado: (2019)

Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel‐group study
por: Nyström, Thomas, et al.
Publicado: (2019)

Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
por: Bhansali, Shipra, et al.
Publicado: (2020)

Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
por: Cummings, Bethany P., et al.
Publicado: (2010)

Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study
por: Du, Guoli, et al.
Publicado: (2020)

The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials
por: Gu, Jianqiu, et al.
Publicado: (2016)

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
por: Liu, Ying, et al.
Publicado: (2017)

Metformin exerts synergistic anti-proliferative effects with liraglutide in human umbilical vein endothelial cells (HUVECs)
por: Shadboorestan, Amir, et al.
Publicado: (2022)

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
por: Nyström, Thomas, et al.
Publicado: (2017)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
por: Jensterle Sever, Mojca, et al.
Publicado: (2014)

Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes
por: Huang, Qi-You, et al.
Publicado: (2020)

Metabolic modelling of the human gut microbiome in type 2 diabetes patients in response to metformin treatment
por: Ezzamouri, Bouchra, et al.
Publicado: (2023)

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
por: Jain, Akshay B., et al.
Publicado: (2020)

1281. Longitudinal and Spatial Variation in the Human Microbiome in a Phase 2a Clinical Study of Gepotidacin in Adult Females with Uncomplicated Urinary Tract Infection
por: Nuzzo, Andrea, et al.
Publicado: (2020)

Beta‐cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?
por: Sayyed Kassem, Laure, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_unkmfoqm1n0b7v7ltnv2jvta99